WINTON GROUP Ltd Trims Stock Holdings in Insulet Co. (NASDAQ:PODD)

WINTON GROUP Ltd reduced its holdings in shares of Insulet Co. (NASDAQ:PODD) by 56.4% in the fourth quarter, Holdings Channel.com reports. The fund owned 4,135 shares of the medical instruments supplier’s stock after selling 5,353 shares during the quarter. WINTON GROUP Ltd’s holdings in Insulet were worth $1,080,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of PODD. Raymond James Financial Inc. bought a new stake in shares of Insulet during the fourth quarter worth $69,433,000. Alecta Tjanstepension Omsesidigt bought a new position in Insulet in the 4th quarter worth about $53,184,000. Artisan Partners Limited Partnership increased its position in shares of Insulet by 24.1% during the fourth quarter. Artisan Partners Limited Partnership now owns 770,188 shares of the medical instruments supplier’s stock worth $201,073,000 after acquiring an additional 149,524 shares during the period. Proficio Capital Partners LLC bought a new stake in shares of Insulet during the fourth quarter valued at approximately $28,422,000. Finally, Baillie Gifford & Co. boosted its holdings in shares of Insulet by 3.5% in the fourth quarter. Baillie Gifford & Co. now owns 2,355,683 shares of the medical instruments supplier’s stock valued at $614,998,000 after purchasing an additional 79,982 shares during the period.

Insider Transactions at Insulet

In other Insulet news, EVP Eric Benjamin sold 12,394 shares of Insulet stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the completion of the transaction, the executive vice president now owns 11,383 shares in the company, valued at approximately $3,187,240. This trade represents a 52.13 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Wayne A.I. Frederick sold 1,825 shares of the company’s stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total value of $501,875.00. Following the completion of the sale, the director now owns 3,231 shares in the company, valued at $888,525. The trade was a 36.10 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.47% of the company’s stock.

Analyst Ratings Changes

PODD has been the subject of several research reports. Wells Fargo & Company upped their target price on Insulet from $305.00 to $322.00 and gave the stock an “overweight” rating in a report on Friday, February 21st. Royal Bank of Canada began coverage on shares of Insulet in a report on Thursday, March 6th. They set an “outperform” rating and a $340.00 target price on the stock. Stifel Nicolaus boosted their price target on shares of Insulet from $245.00 to $293.00 and gave the company a “hold” rating in a report on Friday, February 21st. Raymond James reaffirmed an “outperform” rating and issued a $328.00 price target (up previously from $294.00) on shares of Insulet in a research report on Friday, February 21st. Finally, Canaccord Genuity Group lifted their price objective on shares of Insulet from $304.00 to $324.00 and gave the company a “buy” rating in a report on Friday, February 21st. Four analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $292.06.

Insulet Stock Performance

Shares of Insulet stock opened at $258.75 on Friday. The firm has a market capitalization of $18.17 billion, a P/E ratio of 44.69, a PEG ratio of 3.62 and a beta of 1.29. Insulet Co. has a 52 week low of $160.19 and a 52 week high of $289.46. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. The company has a 50 day moving average price of $271.69 and a 200 day moving average price of $258.53.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, beating analysts’ consensus estimates of $1.00 by $0.15. The firm had revenue of $597.50 million for the quarter, compared to analyst estimates of $582.02 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. Sell-side analysts expect that Insulet Co. will post 3.92 EPS for the current year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.